BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

ASH 2024

More Like This

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

BeiGene Reports First Quarter 2024 Financial Results and Business Updates

(Graphic: Business Wire)

BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates

BerGenBio Reports Third Quarter 2023 Financial Results